Post Archive by Month

The Centers for Disease Control and Prevention (CDC) today issued Health Alert Network Health Advisory (CDCHAN-00514) confirming increases in human parvovirus B19 activity in the United States and Europe.
Parvovirus B19 is a seasonal respiratory virus transmitted through respiratory droplets by people with symptomatic or asymptomatic infection.
In the first quarter of 2024, public health authorities in 14 European countries observed unusually high numbers of parvovirus B19 cases.

The U.S. Centers for Disease Control and Prevention (CDC) recently published an early release (Volume 30, Number 9—September 2024) review of 14 studies in Emerging Infectious Diseases. These researchers wrote that despite the effectiveness of measles-containing vaccines, infection remains possible in immunized persons.
They confirmed measles in persons with secondary vaccination failure (SVF) may be less infectious than cases in unvaccinated persons.
All included studies reported a meager attack rate (0%–6.25%) and Reff (0.063 [95% CI 0.0–0.5]).

The Lancet Infectious Diseases recently published a commentary emphasizing that the chikungunya virus is one of the most neglected arboviral diseases globally, with cases detected in 110 countries.
Chikungunya's impact on people's health has been significant.
Public health authorities in the Region of the Americas have reported approximately 3.7 million chikungunya cases over the past decade. In the United States, this mosquito-transmitted disease is often diagnosed in international travelers returning from chikungunya endemic areas such as Brazil and the Caribbean.

While the 100-year-old BCG vaccine has been used to treat certain bladder cancer pages for years, many patients were seeking a more efficient therapy.

As millions of women and men continue battling the impact of urinary tract infections (UTI), innovative, advanced technology therapies are progressing through clinical trials.
A recent Phase 2 trial evaluating LBP-EC01, a CRISPR-Cas3 genetically engineered bacteriophage therapy designed to treat patients with uncomplicated urinary tract infections (uUTIs) caused by antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli), reported positive news.

As millions of women and men continue battling the impact of urinary tract infections (UTI), innovative, advanced technology therapies are progressing through clinical trials.
A recent Phase 2 trial evaluating LBP-EC01, a CRISPR-Cas3 genetically engineered bacteriophage therapy designed to treat patients with uncomplicated urinary tract infections (uUTIs) caused by antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli), reported positive news.

While numerous countries are confronting dengue fever outbreaks in 2024, with over 11 million cases in the Region of the Americas, there is a pending shift in accessing preventive vaccines.
As of early August 2024, the World Health Organization recommends using a second-generation dengue vaccine: Takeda's QDENGA vaccine. However, there is overwhelming demand, surpassing current vaccine production capabilities.